175 related articles for article (PubMed ID: 14641514)
1. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.
McCrone P; Chisholm D; Knapp M; Hughes R; Comi G; Dalakas MC; Illa I; Kilindireas C; Nobile-Orazio E; Swan A; Van den Bergh P; Willison HJ;
Eur J Neurol; 2003 Nov; 10(6):687-94. PubMed ID: 14641514
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.
Bamrungsawad N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P; Dechanont S; Wu DB; Dejthevaporn C; Chaiyakunapruk N
Clin Drug Investig; 2016 Jul; 36(7):557-66. PubMed ID: 27113227
[TBL] [Abstract][Full Text] [Related]
3. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
Guptill JT; Bromberg MB; Zhu L; Sharma BK; Thompson AR; Krueger A; Sanders DB
Muscle Nerve; 2014 Jul; 50(1):47-51. PubMed ID: 24639235
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes R; Bensa S; Willison H; Van den Bergh P; Comi G; Illa I; Nobile-Orazio E; van Doorn P; Dalakas M; Bojar M; Swan A;
Ann Neurol; 2001 Aug; 50(2):195-201. PubMed ID: 11506402
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
Cochrane Database Syst Rev; 2009 Jan; (1):CD001797. PubMed ID: 19160200
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Afzal S
J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
[TBL] [Abstract][Full Text] [Related]
7. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England.
Mahdi-Rogers M; McCrone P; Hughes RA
Eur J Neurol; 2014; 21(1):34-9. PubMed ID: 23930744
[TBL] [Abstract][Full Text] [Related]
8. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Van Schaik IN; Winer JB; De Haan R; Vermeulen M
Cochrane Database Syst Rev; 2002; (2):CD001797. PubMed ID: 12076423
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
[TBL] [Abstract][Full Text] [Related]
11. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.
Adrichem ME; Bus SR; Wieske L; Mohammed H; Verhamme C; Hadden R; van Schaik IN; Eftimov F
Eur J Neurol; 2020 Mar; 27(3):506-513. PubMed ID: 31571349
[TBL] [Abstract][Full Text] [Related]
12. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
[TBL] [Abstract][Full Text] [Related]
13. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies.
Cocito D; Serra G; Paolasso I; Barilà DA; Lopiano L; Cattel L
J Peripher Nerv Syst; 2012 Dec; 17(4):426-8. PubMed ID: 23279347
[No Abstract] [Full Text] [Related]
14. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Brusse E; Jacobs BC; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Fokkink WR; Nieboer D; Lingsma HF; Merkies ISJ; van Doorn PA
Eur J Neurol; 2021 Jan; 28(1):286-296. PubMed ID: 32876962
[TBL] [Abstract][Full Text] [Related]
16. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany.
Mengel D; Fraune L; Sommer N; Stettner M; Reese JP; Dams J; Glynn RJ; Balzer-Geldsetzer M; Dodel R; Tackenberg B
Muscle Nerve; 2018 Nov; 58(5):681-687. PubMed ID: 30073683
[TBL] [Abstract][Full Text] [Related]
17. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
Perraudin C; Bourdin A; Vicino A; Kuntzer T; Bugnon O; Berger J
PLoS One; 2020; 15(11):e0242630. PubMed ID: 33237959
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.
van Schaik IN; Winer JB; de Haan R; Vermeulen M
Lancet Neurol; 2002 Dec; 1(8):491-8. PubMed ID: 12849334
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
[TBL] [Abstract][Full Text] [Related]
20. Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.
Mason JM; Chalmers JR; Godec T; Nunn AJ; Kirtschig G; Wojnarowska F; Childs M; Whitham D; Schmidt E; Harman K; Walton S; Chapman A; Williams HC;
Br J Dermatol; 2018 Feb; 178(2):415-423. PubMed ID: 28940316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
